Adagio Medical Holdings, Inc.

Robo.ai Announces Core Executive Appointments, Forming a Local UAE Leadership Team at Neurovia AI PR Newswire AB

gurufocus.com - 2026-07-14 02:00:00

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the submission of its Premarket Approval (“PMA”) application to the U.S. Food and Drug Administration (“FDA”) for the vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia (“VT”) in patients with isch.

businesswire.com - 2026-05-21 08:00:00

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the first quarter ended March 31, 2026. Recent Business Highlights: Pivotal results from the FULCRUM-VT trial presented in late-breaking session at Heart Rhythm Society 2026 – the first large-scale, rigorously executed pivotal trial in patients with bot.

businesswire.com - 2026-05-12 08:05:00

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, 2026 at 4:35pm PDT in Las Vegas. Presentation Information A live webcast and replay of the session will be accessible at https://bofa.veracast.com/webcasts/bofa/health.

businesswire.com - 2026-04-29 08:00:00

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #Arrhythmia--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported six month results from its FULCRUM-VT Investigational Device Exemption (“IDE”) clinical trial, which will be used to support the Company's application for Food and Drug Administration (“FDA”) Premarket Approval of the vCLAS Ventricular Ablation System. The results were prese.

businesswire.com - 2026-04-26 09:32:00

Adagio Medical Holdings, Inc. (NASDAQ: ADGM - Get Free Report) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totaling 50,386 shares, an increase of 106.5% from the March 31st total of 24,396 shares. Based on an average trading volume of 299,319 shares, the short-interest

defenseworld.net - 2026-04-26 03:13:08